Ezt az oldalt automatikusan lefordították, és a fordítás pontossága nem garantált. Kérjük, olvassa el a angol verzió forrásszöveghez.

Az inhalációs Molgramostim porlasztó oldat klinikai vizsgálata autoimmun pulmonalis alveoláris proteinózisban (aPAP) (IMPALA-2)

2026. november 2. frissítette: Savara Inc.

Véletlenszerű, kettős vak, placebo-kontrollos klinikai vizsgálat naponta egyszer belélegzett Molgramostim porlasztó oldattal autoimmun pulmonalis alveoláris proteinózisban (aPAP) szenvedő felnőtteknél

160 subjects with autoimmune pulmonary alveolar proteinosis (aPAP) will be randomized to receive once daily treatment with inhaled molgramostim (MOL) or placebo (PBO) for 48 weeks. Subjects completing the 48-week placebo-controlled period will receive open-label treatment with once daily inhaled molgramostim for 96 weeks.

A tanulmány áttekintése

Részletes leírás

This is an interventional, randomized, double-blind, 2-arm, parallel groups, placebo-controlled, multi-center, phase 3 trial in adult subjects who are diagnosed with aPAP.

An aPAP diagnosis should be confirmed by a Granulocyte-macrophage colony stimulating factor (GM-CSF) auto-antibody test result, and history of PAP based on either high resolution computed tomography, lung biopsy, or bronchoalveolar lavage cytology, should be available.

The trial consists of a 6-week screening period, a 48-week randomized, double-blind treatment period, a 96-week open-label treatment period, and a conditional 4-week safety follow-up period. The maximum treatment duration will be 145 weeks and the maximum trial duration will be 156 weeks. During the trial, whole lung lavage will be allowed as rescue treatment in case of worsening of aPAP.

Tanulmány típusa

Beavatkozó

Beiratkozás (Tényleges)

164

Fázis

  • 3. fázis

Kapcsolatok és helyek

Ez a rész a vizsgálatot végzők elérhetőségeit, valamint a vizsgálat lefolytatásának helyére vonatkozó információkat tartalmazza.

Tanulmányi helyek

    • New South Wales
      • Camperdown, New South Wales, Ausztrália, 2050
        • Royal Prince Alfred Hospital
      • Westmead, New South Wales, Ausztrália, 2145
        • Westmead Hospital
    • Brussels Capital
      • Brussels, Brussels Capital, Belgium, 1070
        • Hôpital Erasme
    • Vlaams Brabant
      • Leuven, Vlaams Brabant, Belgium, 3000
        • UZ Leuven - Campus Gasthuisberg - Pneumologie
      • Seoul, Dél -Korea, 03080
        • Seoul National University Hospital
      • Seoul, Dél -Korea, 05505
        • Asan Medical Center
      • Seoul, Dél -Korea, 06351
        • Samsung Medical Center
      • Seoul, Dél -Korea, 03722
        • Severance Hospital - Yonsei University Health System - Pulmonary
    • London
      • London, London, Egyesült Királyság, SW3 6NP
        • Royal Brompton and Harefield NHS Foundation Trust
    • Arkansas
      • Little Rock, Arkansas, Egyesült Államok, 72205
        • University Of Arkansas For Medical Services
    • California
      • Los Angeles, California, Egyesült Államok, 90095
        • UCLA David Geffen School of Medicine
    • Colorado
      • Denver, Colorado, Egyesült Államok, 80206
        • National Jewish Health
    • Connecticut
      • New Haven, Connecticut, Egyesült Államok, 06520
        • Yale University
    • Florida
      • Gainesville, Florida, Egyesült Államok, 32610
        • University of Florida Health
    • Georgia
      • Atlanta, Georgia, Egyesült Államok, 30322
        • Emory University
    • Illinois
      • Maywood, Illinois, Egyesült Államok, 60153
        • Loyola University
    • Maryland
      • Baltimore, Maryland, Egyesült Államok, 21201
        • University of Maryland Medical Center
    • Missouri
      • St Louis, Missouri, Egyesült Államok, 63110
        • Washington University in St. Louis
    • North Carolina
      • Durham, North Carolina, Egyesült Államok, 27710
        • Duke University Medical Center
      • Raleigh, North Carolina, Egyesült Államok, 27610
        • Wake Med Health & Hospital
    • Ohio
      • Cincinnati, Ohio, Egyesült Államok, 45229-3039
        • Cincinnati Children's Hospital Medical Center
      • Cleveland, Ohio, Egyesült Államok, 44195
        • Cleveland Clinic
    • Pennsylvania
      • Philadelphia, Pennsylvania, Egyesült Államok, 19104
        • University of Pennsylvania Perelman School of Medicine - Pulmonology
      • Pittsburgh, Pennsylvania, Egyesült Államok, 15213
        • University of Pittsburgh
    • Texas
      • Dallas, Texas, Egyesült Államok, 75390
        • UT Southwestern Medical Center
    • Auvergne-Rhône-Alpes
      • Bron, Auvergne-Rhône-Alpes, Franciaország, 69500
        • Hôpital Louis Pradel
    • Brittany Region
      • Rennes, Brittany Region, Franciaország, 35033
        • CHU Pontchaillou
      • Athens, Görögország, 12462
        • Attikon University Hospital
    • Utrecht
      • Nieuwegein, Utrecht, Hollandia, 3435CM
        • St Antonius Hospital
      • Nagakute, Japán, 480-1195
        • Aichi Medical University Hospital
    • Chiba
      • Chiba, Chiba, Japán, 260-8677
        • Chiba University Hospital - Respiratory Medicine
    • Hokkaidô
      • Sapporo, Hokkaidô, Japán, 060-8648
        • Hokkaido University Hospital
    • Kanagawa
      • Yokohama, Kanagawa, Japán, 236-0051
        • Kanagawa Cardiovascular and Respiratory Center
    • Kumamoto
      • Kumamoto, Kumamoto, Japán, 860-8556
        • Kumamoto University Hospital
    • Miyagi
      • Sendai, Miyagi, Japán, 980-8574
        • Tohoku University Hospital - Respiratory Tract Medicine
    • Osaka
      • Sakai, Osaka, Japán, 591-8555
        • National Hospital Organization Kinki-Chuo Chest medical Center
    • Saitama
      • Saitama, Saitama, Japán, 330-8553
        • Saitama Red Cross Hospital
    • Tokyo
      • Mitaka, Tokyo, Japán, 181-8611
        • Kyorin University Hospital
    • Alberta
      • Calgary, Alberta, Kanada, T2N 4N1
        • University of Calgary
    • Ontario
      • Hamilton, Ontario, Kanada, L8N 4A6
        • St Joseph's Healthcare Hamilton Research
    • Quebec
      • Québec, Quebec, Kanada, G1V 4G5
        • University Institute of Cardiology and Respirology of Quebec
    • Masovian Voivodeship
      • Warsaw, Masovian Voivodeship, Lengyelország, 01-138
        • Instytut Gruzlicy i Chorob Pluc
    • Baden-Wurttemberg
      • Heidelberg, Baden-Wurttemberg, Németország, 69126
        • Thoraxklinik Heidelberg gGmbH am Universitätsklinikum Heidelberg
    • Bavaria
      • Muenchen-Gauting, Bavaria, Németország, 82131
        • Asklepios Fachkliniken Muenchen-Gauting
    • North Rhine-Westphalia
      • Essen, North Rhine-Westphalia, Németország, 45239
        • Ruhrlandklinik Westdeutsches Lungenzentrum
    • Lombardy
      • Pavia, Lombardy, Olaszország, 27100
        • Fondazione IRCCS Policlinico San Matteo
    • Lisbon District
      • Lisbon, Lisbon District, Portugália, 1769-001
        • Hospital Pulido Valente
    • Porto District
      • Porto, Porto District, Portugália, 4200-319
        • Hospital São João
    • Bucharest
      • Bucharest, Bucharest, Románia, 050159
        • Institutul de Pneumoftiziologie "Marius Nasta"
    • Catalonia
      • Barcelona, Catalonia, Spanyolország, 08907
        • Hospital Universitario de Bellvitge
    • Ankara
      • Ankara, Ankara, Törökország (Türkiye), 6010
        • Health Sciences University Gulhane Training and Research Hospital
    • Istanbul
      • Istanbul, Istanbul, Törökország (Türkiye), 34020
        • Yedikule Chest Disease and Surgery Training and Research Hospital
    • İzmir
      • Bornova, İzmir, Törökország (Türkiye), 35100
        • Ege University Hospital - Department of Pulmonology
      • Dublin, Írország, DO4 T6F4
        • St. Vincent's University Hospital

Részvételi kritériumok

A kutatók olyan embereket keresnek, akik megfelelnek egy bizonyos leírásnak, az úgynevezett jogosultsági kritériumoknak. Néhány példa ezekre a kritériumokra a személy általános egészségi állapota vagy a korábbi kezelések.

Jogosultsági kritériumok

Tanulmányozható életkorok

18 év és régebbi (Felnőtt, Idősebb felnőtt)

Egészséges önkénteseket fogad

Nem

Tanulmányozható nemek

Összes

Leírás

Inclusion Criteria:

  1. Subject must be ≥18 years of age, at the time of signing the informed consent (≥20 in Japan).

  2. A serum anti-GM-CSF autoantibody test result confirming autoimmune PAP.

  3. History of PAP, based on examination of a lung biopsy, bronchoalveolar lavage (BAL) cytology, or a high-resolution computed tomogram (HRCT) of the chest.

  4. A diffusing capacity for carbon monoxide of 70% predicted or lower adjusted for hemoglobin (%DLCOadj) at the screening and baseline visits.

  5. Change in %DLCO adj of <15% points during the screening period.

  6. Demonstrated functional impairment in the treadmill exercise test (defined as a peak metabolic equivalent (MET) ≤8).

  7. Willing and able to come off supplemental oxygen use prior to and during the treadmill exercise test, the DLCO assessment, and the arterial blood gas sampling.

  8. Resting oxygen saturation (SpO2) >85% during 15 minutes without use of supplemental oxygen at the screening visits.

  9. Male or female

  10. Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

    1. Male subjects: Males agreeing to use condoms during and until 30 days after last dose of trial treatment, or males having a female partner who is using adequate contraception as described below.
    2. Female subjects: Females who have been post-menopausal for >1 year, or females of childbearing potential after a confirmed menstrual period using a highly efficient method of contraception (i.e. a method with <1% failure rate such as combined hormonal contraception, progesterone-only hormonal contraception, intrauterine device, intrauterine hormone-releasing system, bilateral tubal occlusion, vasectomized partner, sexual abstinence*), during and until 30 days after last dose of trial treatment. Females of childbearing potential must have a negative serum pregnancy test at the screening visits, and a negative urine pregnancy test at Baseline visit (Visit 3) and must not be lactating.
  11. Capable of giving signed informed consent as described in Appendix 1 which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.

  12. Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other trial procedures specified in the protocol as judged by the Investigator.

Exclusion Criteria:

  1. Diagnosis of hereditary or secondary PAP, or a metabolic disorder of surfactant production.
  2. Whole lung lavage (WLL) performed within 3 months prior to baseline.
  3. Requirement for WLL at screening or baseline.
  4. GM-CSF treatment within 6 months prior to baseline.
  5. Treatment with rituximab within 6 months prior to baseline.
  6. Treatment with plasmapheresis within 6 weeks prior to baseline.
  7. Treatment with any investigational medicinal product within 5 half-lives or 3 months (whichever is longer) prior to baseline.
  8. Previously randomized in this trial.
  9. History of allergic reactions to GM-CSF or any of the excipients in the nebulizer solution.
  10. Inflammatory or autoimmune disease of a severity that necessitates significant (e.g. more than 10 mg/day systemic prednisolone) immunosuppression.
  11. Previous experience of severe and unexplained side-effects during aerosol delivery of any kind of medicinal product.
  12. History of, or present, myeloproliferative disease or leukemia.
  13. Apparent pre-existing concurrent pulmonary fibrosis.
  14. Acute or unstable cardiac or pulmonary disease that may be aggravated by exercise.
  15. Known active infection (viral, bacterial, fungal, or mycobacterial) that may affect the efficacy evaluation in the trial.
  16. Physical disability or other condition that precludes safe and adequate exercise testing.
  17. Any other serious medical condition which in the opinion of the Investigator would make the subject unsuitable for the trial.
  18. Pregnant, planning to become pregnant during the trial, or breastfeeding woman. For France only: including as further defined by French Health Code L-1121-5.
  19. For France only: Any subject considered to be "vulnerable" on account of, e.g., mental or physical disability, socio-economic situation, or subjects deprived of their liberty. For France only: including as further defined by French Health Code L1121-8-1.

Tanulási terv

Ez a rész a vizsgálati terv részleteit tartalmazza, beleértve a vizsgálat megtervezését és a vizsgálat mérését.

Hogyan készül a tanulmány?

Tervezési részletek

  • Elsődleges cél: Kezelés
  • Kiosztás: Véletlenszerűsített
  • Beavatkozó modell: Párhuzamos hozzárendelés
  • Maszkolás: Négyszeres

Fegyverek és beavatkozások

Résztvevő csoport / kar
Beavatkozás / kezelés
Kísérleti: Molgramostim

Double-blind treatment with molgramostim nebulizer solution 300 µg once daily (Mol OD) for 48 weeks

Molgramostim 300 µg nebulizer solution

Más nevek:
  • Rekombináns humán granulocita-makrofág kolónia stimuláló faktor (rhGM-CSF)
Placebo Comparator: Placebo

Double-blind treatment with placebo (PBO) nebulizer solution once daily for 48 weeks

Matching placebo nebulizer solution

Más nevek:
  • Placebo porlasztó
Kísérleti: Molgramostim Open-label Extension

Open-label treatment with molgramostim nebulizer solution 300 µg once daily (Mol OD) for 96 weeks

Molgramostim 300 µg nebulizer solution

Más nevek:
  • Rekombináns humán granulocita-makrofág kolónia stimuláló faktor (rhGM-CSF)

Mit mér a tanulmány?

Elsődleges eredményintézkedések

Eredménymérő
Intézkedés leírása
Időkeret
Change From Baseline in Percent (%) Predicted Diffusing Capacity of the Lung for Carbon Monoxide (DLCO) Adjusted for Hemoglobin Concentration to Week 24
Időkeret: From Baseline to Week 24

As a measure of pulmonary gas transfer, a standardized lung function test, DLCO, was conducted. The single-breath DLCO test was performed in accordance with American Thoracic Society/European Respiratory Society (ATS/ERS) guidelines for DLCO testing. Results reported as % predicted DLCO adjusted for hemoglobin concentration (%predicted DLCOadj).

From Baseline to Week 24

Másodlagos eredményintézkedések

Eredménymérő
Intézkedés leírása
Időkeret
Change From Baseline in Percent (%) Predicted DLCO Adjusted for Hemoglobin Concentration (%DLCOadj) to Week 48
Időkeret: From Baseline to Week 48

As a measure of pulmonary gas transfer, a standardized lung function test, DLCO, was conducted. The single-breath DLCO test was performed in accordance with American Thoracic Society/European Respiratory Society (ATS/ERS) guidelines for DLCO testing. Results reported as % predicted DLCO adjusted for hemoglobin concentration (%predicted DLCOadj). Higher values indicate better respiratory gas exchange.

From Baseline to Week 48
Change From Baseline in St. Georges Respiratory Questionnaire (SGRQ) Total Score to Week 24
Időkeret: From Baseline to Week 24

The Saint Georges Respiratory Questionnaire (SGRQ) is designed to measure respiratory health impairment. The scale includes questions related to three components: Activity (activities that cause or are limited by breathlessness), Impact (social functioning and psychological disturbances resulting from airway disease), and Symptoms (respiratory symptoms, their frequency and severity). The questionnaire has a recall period of 4 weeks for Symptoms, whereas Activity and Impact components address the subject's current state. SGRQ scored on a 0-100 scale with lower scores indicating better respiratory health.

From Baseline to Week 24
Change From Baseline in SGRQ Activity Component Score to Week 24
Időkeret: From Baseline to Week 24

The Saint Georges Respiratory Questionnaire (SGRQ) Activity scale is a subscale of the SGRQ and is designed to measure the effect of respiratory health impairment on daily activity affected by breathlessness. The questionnaire for the Activity components addresses the subject's current state. SGRQ Activity is scored on a 0-100 scale with lower scores indicating better respiratory health activity

From Baseline to Week 24
Change From Baseline in Exercise Capacity (EC), Expressed as Peak Metabolic Equivalents (METs) to Week 24
Időkeret: From Baseline to Week 24

As a functional measure of exertional limitations related to dyspnea, EC was assessed by an exercise treadmill test. EC was expressed in peak METs (1 MET=3.5 mL O2/kg/min). The highest treadmill speed and grade achieved was used to calculate peak METs. Higher values indicate better functional capacity.

From Baseline to Week 24
Change From Baseline in SGRQ Total Score to Week 48
Időkeret: From Baseline to Week 48

The Saint Georges Respiratory Questionnaire (SGRQ) is designed to measure respiratory health impairment. The scale includes questions related to three components: Activity (activities that cause or are limited by breathlessness), Impact (social functioning and psychological disturbances resulting from airway disease), and Symptoms (respiratory symptoms, their frequency and severity). The questionnaire has a recall period of 4 weeks for Symptoms, whereas Activity and Impact components address the subject's current state. SGRQ scored on a 0-100 scale with lower scores indicating better respiratory health.

From Baseline to Week 48
Change From Baseline in SGRQ Activity From Baseline to Week 48
Időkeret: From Baseline to Week 48

The Saint Georges Respiratory Questionnaire (SGRQ) Activity scale is a subscale of the SGRQ and is designed to measure the effect of respiratory health impairment on daily activity affected by breathlessness. The questionnaire for the Activity components addresses the subject's current state. SGRQ Activity is scored on a 0-100 scale with lower scores indicating better respiratory health activity

From Baseline to Week 48
Change From Baseline in EC, Expressed as Peak METs to Week 48
Időkeret: From Baseline to Week 48

As a functional measure of exertional limitations related to dyspnea, EC was assessed by an exercise treadmill test. EC was expressed in peak METs (1 MET=3.5 mL O2/kg/min). The highest treadmill speed and grade achieved was used to calculate peak METs. Higher values indicate better functional capacity.

From Baseline to Week 48
Change From Baseline in Alveolar-arterial Oxygen Difference (A-aDO2) to Week 24 (All Subjects)
Időkeret: From Baseline to Week 24

A-aDO2 was used as an additional measure of gas exchange.

From Baseline to Week 24
Number of Subjects With Serious and Non-serious Adverse Events
Időkeret: From Baseline until End of Double-blind treatment (Week 48)

Assessment of the safety of molgramostim compared to placebo

From Baseline until End of Double-blind treatment (Week 48)
Number of Subjects With Positive Treatment-boosted Anti Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Antibody Titers During 24 Weeks' Treatment and During 48 Weeks' Treatment
Időkeret: From Baseline until End of Double-blind treatment Week-48

Assess the effect of molgramostim or placebo on antiGM-CSF antibody titers that increased by a dilution factor of 2.(4X increase in titer compared to Baseline).

From Baseline until End of Double-blind treatment Week-48
Changes in Forced Vital Capacity (FVC) %Predicted Normal
Időkeret: From Baseline to Weeks 24 and 48

Forced vital capacity is the volume of air that can be expired after a deep breath. Higher volumes indicate better respiratory function. FVC is scored as % of predicted normal expired vital capacity.

From Baseline to Weeks 24 and 48
Changes in Forced Expiratory Volume in One Second (FEV1) % Predicted Normal.
Időkeret: From Baseline to Weeks 24 and 48

FEV1 is the volume of air expired in 1 second in liters (L). Higher values indicate better respiratory function.

From Baseline to Weeks 24 and 48
Change in QT Interval Corrected by Fridericia (QTcF)
Időkeret: From Baseline to Weeks 4 and 24

Assessment of the safety of MOL compared to placebo

From Baseline to Weeks 4 and 24

Együttműködők és nyomozók

Itt találhatja meg a tanulmányban érintett személyeket és szervezeteket.

Szponzor

Nyomozók

  • Kutatásvezető: Bruce Trapnell, MD, Children's Hospital Medical Center, Cincinnati

Publikációk és hasznos linkek

A vizsgálattal kapcsolatos információk beviteléért felelős személy önkéntesen bocsátja rendelkezésre ezeket a kiadványokat. Ezek bármiről szólhatnak, ami a tanulmányhoz kapcsolódik.

Tanulmányi rekorddátumok

Ezek a dátumok nyomon követik a ClinicalTrials.gov webhelyre benyújtott vizsgálati rekordok és összefoglaló eredmények benyújtásának folyamatát. A vizsgálati feljegyzéseket és a jelentett eredményeket a Nemzeti Orvostudományi Könyvtár (NLM) felülvizsgálja, hogy megbizonyosodjon arról, hogy megfelelnek-e az adott minőség-ellenőrzési szabványoknak, mielőtt közzéteszik őket a nyilvános weboldalon.

Tanulmány főbb dátumok

Tanulmány kezdete (Tényleges)

2021. május 19.

Elsődleges befejezés (Tényleges)

2023. november 30.

A tanulmány befejezése (Becsült)

2027. május 30.

Tanulmányi regisztráció dátumai

Először benyújtva

2020. szeptember 3.

Először nyújtották be, amely megfelel a minőségbiztosítási kritériumoknak

2020. szeptember 3.

Első közzététel (Tényleges)

2020. szeptember 10.

Tanulmányi rekordok frissítései

Utolsó frissítés közzétéve (Tényleges)

2026. november 18.

Az utolsó frissítés elküldve, amely megfelel a minőségbiztosítási kritériumoknak

2026. november 2.

Utolsó ellenőrzés

2026. október 1.

Több információ

A tanulmányhoz kapcsolódó kifejezések

Terv az egyéni résztvevői adatokhoz (IPD)

Tervezi megosztani az egyéni résztvevői adatokat (IPD)?

NEM

Gyógyszer- és eszközinformációk, tanulmányi dokumentumok

Egy amerikai FDA által szabályozott gyógyszerkészítményt tanulmányoz

Igen

Egy amerikai FDA által szabályozott eszközterméket tanulmányoz

Nem

Ezt az információt közvetlenül a clinicaltrials.gov webhelyről szereztük be, változtatás nélkül. Ha bármilyen kérése van vizsgálati adatainak módosítására, eltávolítására vagy frissítésére, kérjük, írjon a következő címre: register@clinicaltrials.gov. Amint a változás bevezetésre kerül a clinicaltrials.gov oldalon, ez a webhelyünkön is automatikusan frissül. .

Iratkozz fel